



Dedicated To Life

February 15, 2023

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated February 15, 2023 titled “**Zydus receives tentative approval from the USFDA for Canagliflozin Tablets**”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI

COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives tentative approval from the USFDA for Canagliflozin Tablets

Ahmedabad, India, 15 February, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Canagliflozin Tablets, 100 mg and 300 mg (USRLD: Invokana® Tablets).

Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.

Canagliflozin Tablets had annual sales of USD 660 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 341 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st December 2022)



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878